Learn more

SILENCE THERAPEUTICS GMBH

Overview
  • Total Patents
    167
  • GoodIP Patent Rank
    10,645
  • Filing trend
    ⇧ 119.0%
About

SILENCE THERAPEUTICS GMBH has a total of 167 patent applications. It increased the IP activity by 119.0%. Its first patent ever was published in 2003. It filed its patents most often in EPO (European Patent Office), United States and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are PROSENSA TECH B V, NUCLEONICS INC and BIOMARIN TECH BV.

Patent filings per year

Chart showing SILENCE THERAPEUTICS GMBHs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Frauendorf Christian 58
#2 Hauptmann Judith 49
#3 Bethge Lucas 48
#4 Weingärtner Adrien 33
#5 Kaufmann Jörg 29
#6 Klippel-Giese Anke 28
#7 Keil Oliver 28
#8 Giese Klaus 27
#9 Dames Sibylle 24
#10 Schaeper Ute 20

Latest patents

Publication Filing date Title
WO2021037941A1 Nucleic acids for inhibiting expression of c3 in a cell
WO2020104669A1 Nucleic acids for inhibiting expression of c3 in a cell
WO2020099476A1 Nucleic acids for inhibiting expression of lpa in a cell
EP3730617A1 Nucleic acids for inhibiting expression of c3 in a cell
KR20200140322A SiRNA with vinylphosphonate at the 5'end of the antisense strand
WO2019193189A1 siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS
SG11202003230UA Nucleic acids for inhibiting expression of lpa in a cell
CN111527206A Nucleic acids comprising dithiophosphate linkages for inhibiting expression of target genes
EP3735461A1 Nucleic acids for inhibiting expression of aldh2 in a cell
GB201815836D0 Nucleic acid conjugates
EP3550022A1 Products and compositions
EP3598995A1 Products and compositions
GB201811084D0 Products and compositions
AU2018247924A1 Products and compositions
WO2018185252A1 Nucleic acid conjugates
WO2018185253A1 Ligand modified double-stranded nucleic acids
EP3550021A1 Products and compositions for inhibiting expression of a target gene
EP3549610A1 Nucleic acid conjugates
US2020063133A1 Products and compositions
US2020095580A1 Products and compositions